- Home
- BOLD vs RAPT Comparison
BOLD vs RAPT Comparison
Compare BOLD & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- RAPT
- Stock Information
- Founded
- BOLD 2018
- RAPT 2015
- Country
- BOLD United States
- RAPT United States
- Employees
- BOLD N/A
- RAPT N/A
- Industry
- BOLD
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- RAPT Health Care
- Exchange
- BOLD Nasdaq
- RAPT Nasdaq
- Market Cap
- BOLD 60.4M
- RAPT 65.6M
- IPO Year
- BOLD 2024
- RAPT 2019
- Fundamental
- Price
- BOLD $2.35
- RAPT $1.08
- Analyst Decision
- BOLD Strong Buy
- RAPT Hold
- Analyst Count
- BOLD 3
- RAPT 10
- Target Price
- BOLD $23.00
- RAPT $5.00
- AVG Volume (30 Days)
- BOLD 84.8K
- RAPT 1.1M
- Earning Date
- BOLD 11-07-2024
- RAPT 11-12-2024
- Dividend Yield
- BOLD N/A
- RAPT N/A
- EPS Growth
- BOLD N/A
- RAPT N/A
- EPS
- BOLD N/A
- RAPT N/A
- Revenue
- BOLD N/A
- RAPT N/A
- Revenue This Year
- BOLD N/A
- RAPT N/A
- Revenue Next Year
- BOLD N/A
- RAPT N/A
- P/E Ratio
- BOLD N/A
- RAPT N/A
- Revenue Growth
- BOLD N/A
- RAPT N/A
- 52 Week Low
- BOLD $2.33
- RAPT $1.00
- 52 Week High
- BOLD $15.24
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- RAPT 33.76
- Support Level
- BOLD N/A
- RAPT $1.00
- Resistance Level
- BOLD N/A
- RAPT $1.96
- Average True Range (ATR)
- BOLD 0.00
- RAPT 0.32
- MACD
- BOLD 0.00
- RAPT -0.12
- Stochastic Oscillator
- BOLD 0.00
- RAPT 3.45
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.